[go: up one dir, main page]

WO2008128169A8 - Sparc et procédés pour leur utilisation - Google Patents

Sparc et procédés pour leur utilisation Download PDF

Info

Publication number
WO2008128169A8
WO2008128169A8 PCT/US2008/060213 US2008060213W WO2008128169A8 WO 2008128169 A8 WO2008128169 A8 WO 2008128169A8 US 2008060213 W US2008060213 W US 2008060213W WO 2008128169 A8 WO2008128169 A8 WO 2008128169A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
sparc
paclitaxel
treating
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/060213
Other languages
English (en)
Other versions
WO2008128169A1 (fr
Inventor
Vuong Trieu
Neil P Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Inc USA filed Critical Abraxis Bioscience Inc USA
Priority to ES08745748T priority Critical patent/ES2389828T3/es
Priority to JP2010503267A priority patent/JP5641927B2/ja
Priority to EP08745748A priority patent/EP2146735B1/fr
Priority to CN200880018425.8A priority patent/CN101678078B/zh
Priority to AU2008240117A priority patent/AU2008240117B2/en
Priority to CA002683973A priority patent/CA2683973A1/fr
Publication of WO2008128169A1 publication Critical patent/WO2008128169A1/fr
Publication of WO2008128169A8 publication Critical patent/WO2008128169A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés de traitement des tumeurs mammifères comprenant une thérapie combinée avec des polypeptides SPARC, un inhibiteur de l'angiogénèse et paclitaxel. L'invention concerne également des procédés de traitement des tumeurs mammifères comprenant une thérapie combinée avec des polypeptides SPARC et paclitaxel. De plus, l'invention concerne la production de kits et de procédés pour prédire les réponses à la thérapie.
PCT/US2008/060213 2007-04-13 2008-04-14 Sparc et procédés pour leur utilisation Ceased WO2008128169A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES08745748T ES2389828T3 (es) 2007-04-13 2008-04-14 Composiciones que comprenden polipéptidos SPARC
JP2010503267A JP5641927B2 (ja) 2007-04-13 2008-04-14 Ｓｐａｒｃ及びその使用方法
EP08745748A EP2146735B1 (fr) 2007-04-13 2008-04-14 Compositions comprenant des polypeptides sparc
CN200880018425.8A CN101678078B (zh) 2007-04-13 2008-04-14 Sparc及其使用方法
AU2008240117A AU2008240117B2 (en) 2007-04-13 2008-04-14 SPARC and methods of use thereof
CA002683973A CA2683973A1 (fr) 2007-04-13 2008-04-14 Sparc et procedes pour leur utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92334007P 2007-04-13 2007-04-13
US60/923,340 2007-04-13

Publications (2)

Publication Number Publication Date
WO2008128169A1 WO2008128169A1 (fr) 2008-10-23
WO2008128169A8 true WO2008128169A8 (fr) 2009-07-16

Family

ID=39591630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/060213 Ceased WO2008128169A1 (fr) 2007-04-13 2008-04-14 Sparc et procédés pour leur utilisation

Country Status (8)

Country Link
US (1) US20080255035A1 (fr)
EP (1) EP2146735B1 (fr)
JP (2) JP5641927B2 (fr)
CN (1) CN101678078B (fr)
AU (1) AU2008240117B2 (fr)
CA (1) CA2683973A1 (fr)
ES (1) ES2389828T3 (fr)
WO (1) WO2008128169A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081096A2 (fr) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Nanoparticules ciblant les récepteurs pour une administration de médicament médiée par transcytose améliorée
NZ623264A (en) 2008-12-05 2015-09-25 Abraxis Bioscience Llc Sparc binding scfvs
AU2010224031B2 (en) * 2009-03-11 2013-05-02 Abraxis Bioscience, Llc SPARC angiogenic domain and methods of use
US20120245089A1 (en) * 2009-09-18 2012-09-27 Abraxis Bioscience, Llc Use of the sparc microenvironment signature in the treatment of cancer
LT2506840T (lt) 2009-12-04 2021-06-25 OncoC4, Inc. Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
KR101786142B1 (ko) * 2010-03-26 2017-10-17 아브락시스 바이오사이언스, 엘엘씨 간세포 암종의 치료 방법
RU2589513C2 (ru) 2010-03-29 2016-07-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
EP2552439B1 (fr) 2010-03-29 2022-07-20 Abraxis BioScience, LLC Méthodes d'amélioration de l'administration de médicament et de l'efficacité d'agents thérapeutiques
PH12012502378A1 (en) * 2010-06-02 2013-02-11 Abraxis Bioscience Llc Methods of treating bladder cancer
CN103002905A (zh) 2010-06-03 2013-03-27 阿布拉西斯生物科学有限责任公司 Sparc微环境标签在癌症治疗中的应用
US9089150B2 (en) * 2011-05-27 2015-07-28 National Cheng Kung University Method for lowering feed conversion rate
EP2817010B1 (fr) * 2012-02-21 2018-08-08 Tactical Therapeutics, Inc. Compositions d'amélioration de la sensibilité de médicaments cytotoxiques avec une thérapie combinatoire opportune avec de l'orotate de carboxyamidotriazole
HRP20181187T1 (hr) 2012-04-04 2018-09-21 Halozyme, Inc. Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor
BR112016022499A2 (pt) * 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd Produtos terapêuticos combinatórios supramoleculares
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
IL260933B2 (en) 2016-02-08 2023-04-01 Beyondspring Pharmaceuticals Inc Preparations containing tocorsol or its analogues
KR20190015361A (ko) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
WO2018144764A1 (fr) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Méthode de réduction de la neutropénie
EP3743074A4 (fr) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. Composition et procédé pour réduire la thrombocytopénie par l'administration de plinabuline
CN108392483B (zh) * 2018-04-18 2019-11-19 郑州大学 一种紫杉醇联合2-甲氧基雌二醇的白蛋白纳米粒的制备方法及应用
JP2018199726A (ja) * 2018-09-26 2018-12-20 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
WO2022217283A1 (fr) 2021-04-08 2022-10-13 Joslin Diabetes Center, Inc. Procédés de diagnostic et de prédiction de déclin rénal
CA3215047A1 (fr) 2021-04-09 2022-10-13 Lan Huang Compositions therapeutiques et methodes de traitement de tumeurs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945515A (en) * 1995-07-31 1999-08-31 Chomczynski; Piotr Product and process for isolating DNA, RNA and proteins
US6387664B1 (en) * 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
WO2003009817A2 (fr) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
CA2802143C (fr) * 2003-01-14 2018-06-19 Dana-Farber Cancer Institute Polynucleotide codant un sparc comme agent sensibilisant de therapie du cancer
EP2784082B1 (fr) * 2004-05-14 2017-12-27 Abraxis BioScience, LLC Compositions pharmaceutiques comprenant du paclitaxel pour l'apport a des sites pathologiques
ATE527370T1 (de) 2004-11-30 2011-10-15 Univ British Columbia Sparc-promotormutationen im zusammenhang mit arzneistoffresistenz sowie damit verbundene verfahren
AU2006237613A1 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 SPARC deletion mutant and uses thereof
JP5590882B2 (ja) * 2006-06-26 2014-09-17 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 化学療法増感剤としてのシステインに富む酸性分泌タンパク質（ｓｐａｒｃ）

Also Published As

Publication number Publication date
EP2146735A1 (fr) 2010-01-27
EP2146735B1 (fr) 2012-06-20
CN101678078A (zh) 2010-03-24
US20080255035A1 (en) 2008-10-16
AU2008240117A1 (en) 2008-10-23
CA2683973A1 (fr) 2008-10-23
WO2008128169A1 (fr) 2008-10-23
AU2008240117B2 (en) 2013-12-05
CN101678078B (zh) 2014-12-10
ES2389828T3 (es) 2012-11-02
JP5641927B2 (ja) 2014-12-17
JP2010526031A (ja) 2010-07-29
JP2014169293A (ja) 2014-09-18

Similar Documents

Publication Publication Date Title
WO2008128169A8 (fr) Sparc et procédés pour leur utilisation
WO2010009337A3 (fr) Signatures et déterminants de la pc associés au cancer de la prostate et leurs procédés d’utilisation
BRPI0916121A8 (pt) métodos para identificar câncer de próstata, composição, kit, método para identificar a presença de uma fusão gênica e uso de uma composição
WO2007095638A3 (fr) Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
WO2009108860A3 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
PH12017500930A1 (en) Hsp90 inhibitor combinations
WO2008046911A3 (fr) Nouveaux microarn humains associés au cancer
WO2009009173A3 (fr) Klotho bêta
MX2012013256A (es) Composiciones y metodos para el tratamiento de leucemia.
CL2011002739A1 (es) Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras.
CR10995A (es) Inhibidores de la actividad de akt
WO2007061874A3 (fr) Procedes et compositions utilises dans le traitement du cancer
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
CL2007001269A1 (es) Compuestos derivados de heterociclos de nitrogeno, moduladores de vias de hedgehog; y uso para el tratamiento de cancer pancreatico, cancer de prostata, meduloblastoma, carcinoma celular basal y cancer pulmonar de celula pequena.
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
WO2008150530A3 (fr) Molécules de liaison de cripto
WO2009015037A3 (fr) Indazoles substitués par du 5-pyridinone
EP2670989A4 (fr) Nouvelle clé d'assemblage, kits de porte et procédés d'utilisation de ces derniers
WO2009158374A3 (fr) Inhibiteurs d’activité akt
WO2012050963A3 (fr) Agents fournissant des témoins et des étalons pour des tests d'immunoprécipitation
WO2008070472A3 (fr) Utilisation de plasma hsp90 lié à une malignité
WO2007030611A3 (fr) Indice calcule d'expression genomique de recepteurs des oestrogenes (er) et genes associes aux er
EA201100882A1 (ru) Профилактическое/терапевтическое средство против рака

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880018425.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08745748

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008240117

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010503267

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2683973

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 6782/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008240117

Country of ref document: AU

Date of ref document: 20080414

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008745748

Country of ref document: EP